We are live on ! Find out more
CPX

Canaan Partners XI Portfolio holdings

AUM $127M
1-Year Est. Return 217.49%
This Fund
S&P 500
This Quarter Est. Return
+17.57%
1 Year Est. Return
+217.49%
3 Year Est. Return
+1,311.52%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$248M
AUM Growth
-$32.9M
Cap. Flow
-$57.4M
Cap. Flow %
-23.15%
Top 10 Hldgs %
100%
Holding
6
New
–
Increased
–
Reduced
1
Closed
–

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
DAWN
Day One Biopharmaceuticals
DAWN
+$57.4M

Sector Composition

Rank Sector Weight
1 Healthcare 86.05%
2 Technology 13.94%
3 Consumer Discretionary 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DAWN
1
DELISTED
Day One Biopharmaceuticals
DAWN
$139M 56.26%
6,964,301
-2,699,344
-28% -$57.4M
TYRA icon
2
Tyra Biosciences
TYRA
$1.91B
$38.8M 15.63%
4,409,991
– –
RLYB icon
3
Rallybio
RLYB
$84.6M
$34.9M 14.06%
301,214
– –
AEVA
4
Aeva Technologies
AEVA
$1.26B
$34.6M 13.94%
3,697,039
– –
VECT
5
DELISTED
VectivBio Holding AG Ordinary Shares
VECT
$222K 0.09%
37,051
– –
BRDS
6
DELISTED
Bird Global, Inc.
BRDS
$24K 0.01%
2,771
– –

Similar funds

CF
Concorde Financial Dallas, Texas $127M AUM 24.97% 1-Year Est. Return
MF
Midwestern Financial Iowa City, Iowa $127M AUM 13.96% 1-Year Est. Return
SAP
Strategic Advisory Partners Greensboro, North Carolina $127M AUM
S
Storgate Dallas, Texas $127M AUM
PIP
PB Investment Partners Burlingame, California $127M AUM 0.83% 1-Year Est. Return
VDC
Van Diest Capital Poly City, Iowa $127M AUM
SIM
Summitas Investment Management Mckinney, Texas $128M AUM
PC
Pelham Capital London, United Kingdom $128M AUM 34.73% 1-Year Est. Return

Canaan Partners XI's Q3 2022 Portfolio in Review

As of Q3 2022, Canaan Partners XI held 6 positions worth $248M, down 12% from $281M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Canaan Partners XI withdrew a net $57.4M in Q3 2022, reducing 1 holding. Its largest reduction was Day One Biopharmaceuticals, cutting an estimated $57.4M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 79% a quarter earlier, followed by Technology and Consumer Discretionary.

  • Canaan Partners XI's biggest Q3 2022 reduction was Day One Biopharmaceuticals, cutting an estimated $57.4M.
  • Canaan Partners XI's ten largest holdings make up 100% of its $248M portfolio in Q3 2022.
  • Canaan Partners XI opened 0 new positions and closed 0 in Q3 2022.
  • Canaan Partners XI's portfolio value fell 12% quarter-over-quarter to $248M.

Based on Canaan Partners XI's 13F filing for Q3 2022, filed 31 Oct 2022.